scholarly journals The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients’ Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2925
Author(s):  
Soo Young Jun ◽  
Hyang Ran Yoon ◽  
Ji-Yong Yoon ◽  
Su-Jin Jeon ◽  
Jeong-Ju Lee ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Cancer Cell ◽  
Characteristic Curve ◽  
Tor Signaling ◽  
Kaplan Meier ◽  
Cancer Aggressiveness ◽  
Liver Cancers ◽  
Potential Biomarkers

Recently, we reported the involvement of TIPRL/LC3/CD133 in liver cancer aggressiveness. This study assessed the human TOR signaling regulator (TIPRL)/microtubule-associated light chain 3 (LC3)/prominin-1 (CD133)/cluster of differentiation 44 (CD44) as potential diagnostic and prognostic biomarkers for early liver cancer. For the assessment, we stained tissues of human liver disease/cancer with antibodies against TIPRL/LC3/CD133/CD44/CD46, followed by confocal observation. The roles of TIPRL/LC3/CD133/CD44/CD46 in liver normal and cancer cell lines were determined by in vitro studies. We analyzed the prognostic and diagnostic potentials of TIPRL/LC3/CD133/CD44/CD46 using the receiver-operating characteristic curve, a Kaplan–Meier and uni-/multi-Cox analyses. TIPRL and LC3 were upregulated in tissues of HCCs and adult hepatocytes-derived liver diseases while downregulated in iCCA. Intriguingly, TIPRL levels were found to be critically associated with liver cancer patients’ survivability, and TIPRL is the key player in liver cancer cell proliferation and viability via stemness and self-renewal induction. Furthermore, we demonstrate that TIPRL/LC3/CD133 have shown prominent efficiency for diagnosing patients with grade 1 iCCA. TIPRL/LC3/CD133/CD44 have also provided excellent potential for prognosticating patients with grade 1 iCCA and grade 1 HCCs, together with demonstrating that TIPRL/LC3/CD133/CD44 are, either individually or in conjunction, potential biomarkers for early liver cancer.

Abstract 2414: In vitro profiling of gastric and liver cancer cell lines developed from Asian cancer patients

2011 ◽  
Author(s):  
Gerhard Kelter ◽  
Armin Maier ◽  
Rebekka Krumbach ◽  
Julia Schüler ◽  
Heinz-Herbert Fiebig ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Liver Cancer Cell

KLa(0.95−x)GdxF4:Eu3+ hexagonal phase nanoparticles as luminescent probes for in vitro Huh-7 cancer cell imaging

2021 ◽  
Vol 50 (15) ◽  
pp. 5197-5207
Author(s):  
Mohini Gupta ◽  
Rajamani Nagarajan ◽  
Chitteti Ramamurthy ◽  
Perumal Vivekanandan ◽  
G. Vijaya Prakash
Keyword(s):  
Liver Cancer ◽  
Cancer Cell ◽  
Cell Imaging ◽  
Hexagonal Phase ◽  
Liver Cancer Cell ◽  
Luminescent Probes ◽  
Cancer Cell Imaging ◽  
Site Selective

Strong and site selective red-emitting photoluminescent/MRI multi-functional KLa(0.95−x)GdxF4:Eu3+ (x = 0–0.4) bio-compatible nanomaterials for targeted in-vitro liver cancer cell imaging.

scholarly journals Quercetin Suppresses Proliferation of Liver Cancer Cell Lines In Vitro

2020 ◽  
Vol 40 (8) ◽  
pp. 4695-4700 ◽  
Author(s):  
TORU HISAKA ◽  
HISAMUNE SAKAI ◽  
TOSHIHIRO SATO ◽  
YUICHI GOTO ◽  
YORIKO NOMURA ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Liver Cancer Cell

scholarly journals Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo

2019 ◽  
Vol 39 (11) ◽  
pp. 5973-5982 ◽  
Author(s):  
SACHIKO OGASAWARA ◽  
YUTARO MIHARA ◽  
REIICHIRO KONDO ◽  
HIRONORI KUSANO ◽  
JUN AKIBA ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Human Liver ◽  
Antiproliferative Effect ◽  
Liver Cancer Cell ◽  
Human Liver Cancer Cell ◽  
Human Liver Cancer

scholarly journals IN VITRO GROWTH INHIBITORY EFFECT OF ZnO NANOPARTICLES ON HUMAN LIVER CANCER CELL LINES (Huh7)

2019 ◽  
pp. 191-193
Author(s):  
ANANTHALAKSHMI R ◽  
XAVIER RAJARATHINAM SR ◽  
Mohamed Sadiq A ◽  
MOHAMED SADIQ A
Keyword(s):  
Liver Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Zno Nanoparticles ◽  
Huh7 Cell ◽  
Cancer Cell Lines ◽  
Inhibitory Effect ◽  
Liver Cancer Cell ◽  
Zno Nps

Objective: The objective of the study was to access the anticancer activity of the biosynthesized ZnO nanoparticles against Huh7 liver cancer cell lines. Methods: The study was carried in vitro using Huh7 cell lines. The ZnO nanoparticles (ZnO NPs) were synthesized using Luffa acutangula peel extract and subjected to characterization by X-ray powder diffraction and transmission electron microscopy. The Huh7 cell lines were treated with ZnO NPs and done 3-(4, 5-dimethylthiazol- 2-yl)-2, 5-diphenyltetrazolium bromide assay. For live and dead assay, the cell lines treated with ZnO NPs were subjected to acridine orange/ethidium (AO/ET) bromide assay. Results: The ZnO NPs synthesized show spherical structure with 10–20 nm size. The 50% of Huh7 proliferation were inhibited at the concentration (IC50) of 40 μg/ml. The AO/ET assay shows compact nucleus and fine cytoplasmic morphology in control cells and apoptotic stage in treated cells Conclusion: This study suggests that ZnO NPs can be prepared in environment-friendly method using aqueous extract of L. acutangula and can be used in cancer treatment effectively.

Interferon-αCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo

2004 ◽  
Vol 41 (5) ◽  
pp. 782-789 ◽  
Author(s):  
Toru Hisaka ◽  
Hirohisa Yano ◽  
Sachiko Ogasawara ◽  
Seiya Momosaki ◽  
Naoyo Nishida ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Liver Cancer Cell

Treatment and survival outcomes for Medicaid patients with pancreatic, colon-rectosigmoid, and liver cancers at a national comprehensive cancer center.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18524-e18524
Author(s):  
Andrea M. Schiefelbein ◽  
Amy K. Taylor ◽  
John K. Krebsbach ◽  
Patrick Varley ◽  
John M. Hampton ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Private Insurance ◽  
Survival Outcomes ◽  
Distant Disease ◽  
Rectosigmoid Cancer ◽  
Risk Of Death ◽  
Academic Medical ◽  
Liver Cancers ◽  
To Receive

e18524 Background: Treatment and survival disparities faced by Medicaid patients are documented for pancreatic, colon-rectosigmoid, and liver cancers at a national level. Studies show these disparities persist at academic medical centers. We assessed Medicaid treatment and survival outcomes among University of Wisconsin-Health (UWH) pancreatic, colon-rectosigmoid, and liver cancer patients to determine whether national trends persisted at this academic medical center. Methods: We included UWH registry data for 1567 pancreatic, 2313 colon-rectosigmoid, and 1027 liver cancer patients ages 18+ from 2004-2016. We performed multivariable logistic regression to estimate odds ratios (ORs) to assess insurance disparities in intended resection and Cox Proportional regression to estimate hazard ratios (HRs) to assess all-cause mortality disparities for each cancer, adjusting for age, sex, race/ethnicity, BMI, comorbidity, stage, rurality, and insurance. Results: Median overall survival was 6.5 months (range 0.1-147.5) for pancreatic, 12.8 months (0.1-167.5) for colon-rectosigmoid, and 12.5 months (0.1-168.7) for liver cancer patients. 3% of pancreatic, 5% of colon-rectosigmoid, and 9% of liver cancer patients had Medicaid Insurance. Medicaid patients were less likely to be older and non-Hispanic White than private insurance (private) patients for each cancer. Medicaid patients were diagnosed with more distant disease for colon-rectosigmoid and liver cancers and less distant disease for pancreatic cancer. Medicaid patients were less likely to receive surgery vs private patients for pancreatic (OR 0.41, 95% CI 0.16-1.08) and liver (OR 0.62, 0.26-1.49) cancers, though confidence intervals were wide. Insurance was not associated with surgery in colon-rectosigmoid cancer patients (OR 0.97, 0.48-1.97). Medicaid patients had a higher risk of death vs private patients for colon rectosigmoid cancer (HR 1.50, 1.12-2.01). Risk of death was modestly elevated for Medicaid vs private patients for pancreatic (HR 1.35, 0.97-1.87) but not liver (HR 1.07, 0.77-1.48) cancer. Conclusions: Medicaid pancreatic and liver cancer patients may be less likely to receive surgery than private patients in our one center study. Results suggested that Medicaid pancreatic and colon-rectosigmoid cancer patients may have a slightly elevated risk of death vs private patients, though this needs confirmation in larger samples. Future studies should explore at which local, state, and regional levels Medicaid pancreatic, colon-rectosigmoid, and liver cancer patients experience treatment and survival disparities vs private insurance patients. These studies, combined with Medicaid expansion studies, can guide healthcare leaders and policy makers to design context-appropriate interventions to reduce insurance-related disparities in cancer treatment and outcomes.

Sign in / Sign up

Export Citation Format

Share Document